(ORNBV) Orion - HE
Sector: Healthcare | Industry: Drug Manufacturers - General | Exchange: HE (Finland) | Market Cap: 9.609m EUR | Total Return: 9.4% in 12m
Avg Turnover: 12.4M
EPS Trend: 82.7%
Qual. Beats: -1
Rev. Trend: 92.1%
Qual. Beats: 0
Warnings
Below Avwap Earnings
Tailwinds
Confidence
Orion Oyj is a Finland-based pharmaceutical company that develops, manufactures, and markets human and veterinary medicines alongside active pharmaceutical ingredients (APIs). Its portfolio spans diverse therapeutic areas, including oncology, neurology, respiratory diseases, and intensive care, with key products such as Nubeqa for prostate cancer and the Easyhaler range for asthma and COPD.
The company operates a hybrid business model, combining the development of proprietary drugs with the production of generic compounds and contract manufacturing services. In the pharmaceutical sector, long-term growth is often driven by strategic licensing agreements, such as Orion’s partnerships with Bayer and Tenax Therapeutics to expand the commercial reach of its clinical pipeline.
Investors may find additional insights on the companys valuation metrics by reviewing the data on ValueRay. Founded in 1917 and headquartered in Espoo, Orion maintains an international presence across Europe, North America, and global markets, supported by a distribution network that includes online sales and non-prescription self-care products.
- Nubeqa sales growth and royalty income drive oncology revenue expansion
- Easyhaler portfolio performance and market share gains in respiratory segment
- R&D pipeline progression and clinical trial outcomes for proprietary drugs
- Generic competition and patent expirations impact mature Parkinson’s disease franchise
| Net Income: 529.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -1.66 > 1.0 |
| NWC/Revenue: 31.38% < 20% (prev 50.78%; Δ -19.40% < -1%) |
| CFO/TA 0.13 > 3% & CFO 276.3m > Net Income 529.4m |
| Net Debt (145.6m) to EBITDA (722.1m): 0.20 < 3 |
| Current Ratio: 1.77 > 1.5 & < 3 |
| Outstanding Shares: last quarter (140.7m) vs 12m ago 0.12% < -2% |
| Gross Margin: 64.79% > 18% (prev 61.53%; Δ 3.26% > 0.5%) |
| Asset Turnover: 103.3% > 50% (prev 93.31%; Δ 9.96% > 0%) |
| Interest Coverage Ratio: 154.8 > 6 (EBIT TTM 665.8m / Interest Expense TTM 4.30m) |
| A: 0.29 (Total Current Assets 1.41b - Total Current Liabilities 798.6m) / Total Assets 2.08b |
| B: 0.49 (Retained Earnings 1.02b / Total Assets 2.08b) |
| C: 0.35 (EBIT TTM 665.8m / Avg Total Assets 1.89b) |
| D: 1.17 (Book Value of Equity 1.12b / Total Liabilities 956.8m) |
| Altman-Z'' = 7.13 = AAA |
| DSRI: 1.49 (Receivables 699.6m/381.9m, Revenue 1.95b/1.59b) |
| GMI: 0.95 (GM 61.53% / 64.79%) |
| AQI: 0.87 (AQ_t 0.10 / AQ_t-1 0.12) |
| SGI: 1.23 (Revenue 1.95b / 1.59b) |
| TATA: 0.12 (NI 529.4m - CFO 276.3m) / TA 2.08b) |
| Beneish M = -2.57 (Cap -4..+1) = A |
As of June 20, 2026, the stock is trading at EUR 67.35 with a total of 1,014,791 shares traded.
Over the past week, the price has changed by -2.11%,
over one month by -2.32%,
over three months by -4.40% and
over the past year by +9.41%.
Orion has no consensus analysts rating.
P/E Trailing = 18.1383
P/E Forward = 29.4985
P/S = 4.9209
P/B = 8.4778
P/EG = 5.7296
Revenue TTM = 1.95b EUR
EBIT TTM = 665.8m EUR
EBITDA TTM = 722.1m EUR
Long Term Debt = 105.9m EUR (from longTermDebt, last fiscal year)
Short Term Debt = 219.7m EUR (from shortTermDebt, last quarter)
Debt = 344.9m EUR (from shortLongTermDebtTotal, last quarter) + Leases 14.6m
Net Debt = 145.6m EUR (calculated: Debt 344.9m - CCE 199.3m)
Enterprise Value = 9.75b EUR (9.61b + Debt 344.9m - CCE 199.3m)
Interest Coverage Ratio = 154.8 (Ebit TTM 665.8m / Interest Expense TTM 4.30m)
EV/FCF = 53.39x (Enterprise Value 9.75b / FCF TTM 182.7m)
FCF Yield = 1.87% (FCF TTM 182.7m / Enterprise Value 9.75b)
FCF Margin = 9.36% (FCF TTM 182.7m / Revenue TTM 1.95b)
Net Margin = 27.12% (Net Income TTM 529.4m / Revenue TTM 1.95b)
Gross Margin = 64.79% ((Revenue TTM 1.95b - Cost of Revenue TTM 687.4m) / Revenue TTM)
Gross Margin QoQ = 60.81% (prev 73.16%)
Tobins Q-Ratio = 4.69 (Enterprise Value 9.75b / Total Assets 2.08b)
Interest Expense / Debt = 1.25% (Interest Expense 4.30m / Debt 344.9m)
Taxrate = 20.31% (134.9m / 664.2m)
NOPAT = 530.6m (EBIT 665.8m * (1 - 20.31%))
Current Ratio = 1.77 (Total Current Assets 1.41b / Total Current Liabilities 798.6m)
Debt / Equity = 0.31 (Debt 344.9m / totalStockholderEquity, last quarter 1.12b)
Debt / EBITDA = 0.20 (Net Debt 145.6m / EBITDA 722.1m)
Debt / FCF = 0.80 (Net Debt 145.6m / FCF TTM 182.7m)
Total Stockholder Equity = 1.09b (last 4 quarters mean from totalStockholderEquity)
RoA = 28.00% (Net Income 529.4m / Total Assets 2.08b)
RoE = 48.73% (Net Income TTM 529.4m / Total Stockholder Equity 1.09b)
RoCE = 55.84% (EBIT 665.8m / Capital Employed (Equity 1.09b + L.T.Debt 105.9m))
RoIC = 37.83% (NOPAT 530.6m / Invested Capital 1.40b)
WACC = 7.08% (E(9.61b)/V(9.95b) * Re(7.30%) + D(344.9m)/V(9.95b) * Rd(1.25%) * (1-Tc(0.20)))
Discount Rate = 7.30% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 33.33 | Cagr: 0.12%
[DCF] Terminal Value 75.80% ; FCFF base≈180.7m ; Y1≈185.6m ; Y5≈205.8m
[DCF] Fair Price = 27.80 (EV 3.19b - Net Debt 145.6m = Equity 3.04b / Shares 109.3m; r=8.35% [WACC [floored]]; 5y FCF grow 2.76% → 2.50% )
EPS Correlation: 82.69 | EPS CAGR: 35.98% | SUE: -1.14 | # QB: -1
Revenue Correlation: 92.13 | Revenue CAGR: 19.85% | SUE: -0.18 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.99 | Chg30d=+1.03% | Revisions=+25% | Analysts=5
EPS next Quarter (2026-09-30): EPS=1.12 | Chg30d=+0.58% | Revisions=+50% | Analysts=5
EPS current Year (2026-12-31): EPS=3.91 | Chg30d=+1.19% | Revisions=+33% | GrowthEPS=+9.8% | GrowthRev=+10.1%
EPS next Year (2027-12-31): EPS=4.61 | Chg30d=+3.40% | Revisions=+56% | GrowthEPS=+18.0% | GrowthRev=+13.0%
[Analyst] Revisions Ratio: +56%